Anavex Life Sciences Corp (AVXL)

[hapit]

I liked this part of the conference call.

“we believe that the genomic data what we have seen and the data will be presented at scientific meeting is relevant for the compound -- in the interaction with the compound, and that means, if the impact on all future studies and that information will be applied -- the stratification will be able to applied in all future studies of ANAVEX2-73 and because of it is known that biomarker based on gene information has a significant advantage because it makes patient groups more homogeneous that also result in a higher chances of succeeding in clinical trials among other things being equal, and that's been provided in the literature very extensively. And so we are using really the same path of clinical study of [rigor] to applying to the CNS indications Rett Syndrome, Parkinson's with dementia and Alzheimer's disease, which so far has been only applied to oncology and that's also something which Anavex believes is at the forefront in that regard.”